From GlobeNewswire: 2025-02-13 21:45:11

InflaRx N.V., a biopharmaceutical company, announced a public offering of 8,250,000 ordinary shares at $2.00 per share and pre-funded warrants for up to 6,750,000 shares. The offering is expected to close on February 18, 2025, with net proceeds intended for clinical development and corporate purposes. Guggenheim Securities, LLC is the book-running manager, with H.C. Wainwright & Co. and Lucid Capital Markets, LLC as co-lead managers. The offering is made under a shelf registration statement declared effective by the SEC in 2023. InflaRx is focused on developing anti-inflammatory therapeutics targeting the complement system.



Read more at GlobeNewswire: InflaRx Announces Pricing of $30 Million Public Offering of